Printer Friendly

TEXAS BIOTECHNOLOGY APPOINTS JOHN PLACHETKA VICE PRESIDENT OF CLINICAL DEVELOPMENT

 HOUSTON, Aug. 2 /PRNewswire/ -- Texas Biotechnology Corporation (TBC) today announced it has named John R. Plachetka, Pharm.D., vice president of clinical development. Dr. Plachetka has more than 15 years experience in biomedical research and pharmaceutical development.
 "Dr. Plachetka comes to us with a wealth of experience in the clinical development area, most notably with expertise in cardiovascular research," said David B. McWilliams, president and chief executive officer of TBC. "His clinical background and experience interfacing with the Food and Drug Administration will prove paramount to TBC's development as we commercialize our technology. We expect to be in the clinic later this year with Agratroban, our recently license drug from Genentech."
 Dr. Plachetka's responsibilities at TBC will include all clinical development activities including clinical research, biostatistics and data management, regulatory affairs and pharmaceutics.
 Prior to joining TBC, Dr. Plachetka, 40, was the president and chief executive officer of Clinical Research Foundation--America (CRF), one of the largest contract clinical research organizations in the nation, where he successfully restructured the business and built a new 30,000-square-foot U.S. headquarters. CRF was recently purchased by Innovex, located in the United Kingdom.
 Previous to his post at Clinical Research Foundation, Dr. Plachetka spent nine years at Glaxo, Inc. in various senior research positions, including director of cardiovascular clinical research. During his tenure at Glaxo, Dr. Plachetka coordinated several NDA approval programs, which included the recently approved Imitrex injection.
 Dr. Plachetka received his Pharm.D. from the University of Missouri- Kansas City and a B.S. in pharmacy from the University of Illinois. Currently, he is an adjunct professor at Duke University.
 Texas Biotechnology is a privately held company based in Houston. The company's research is focused on the endothelium, the layer of cells lining blood vessels. The company is developing proprietary molecules to treat various cardiovascular diseases including arterial restenosis and atherosclerosis.
 -0- 8/2/93
 /CONTACT: David B. McWilliams, president and CEO of Texas Biotechnology Corporation, 713-796-8822, or Anthony J. Russo, Ph.D., of Noonan/Russo Communications, 212-696-4455, for Texas Biotechnology Corporation/


CO: Texas Biotechnology Corporation ST: Texas IN: MTC SU: PER

PS-MP -- NY062 -- 8365 08/02/93 12:20 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Aug 2, 1993
Words:359
Previous Article:INTRENET REPORTS PROFITABLE SECOND QUARTER AND FIRST HALF
Next Article:BAROID CORPORATION ANNOUNCES THIRD QUARTER DIVIDEND
Topics:

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters